JP2019520063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520063A5 JP2019520063A5 JP2018562201A JP2018562201A JP2019520063A5 JP 2019520063 A5 JP2019520063 A5 JP 2019520063A5 JP 2018562201 A JP2018562201 A JP 2018562201A JP 2018562201 A JP2018562201 A JP 2018562201A JP 2019520063 A5 JP2019520063 A5 JP 2019520063A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- binds
- positions
- pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021184049A JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342167P | 2016-05-26 | 2016-05-26 | |
| US62/342,167 | 2016-05-26 | ||
| PCT/US2017/030676 WO2017205014A1 (en) | 2016-05-26 | 2017-05-02 | Mixtures of antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184049A Division JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520063A JP2019520063A (ja) | 2019-07-18 |
| JP2019520063A5 true JP2019520063A5 (https=) | 2020-06-18 |
| JP7301540B2 JP7301540B2 (ja) | 2023-07-03 |
Family
ID=58709577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562201A Active JP7301540B2 (ja) | 2016-05-26 | 2017-05-02 | 抗体の混合物 |
| JP2021184049A Withdrawn JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184049A Withdrawn JP2022010244A (ja) | 2016-05-26 | 2021-11-11 | 抗体の混合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11130808B2 (https=) |
| EP (1) | EP3463451A1 (https=) |
| JP (2) | JP7301540B2 (https=) |
| CN (1) | CN109475627B (https=) |
| AU (1) | AU2017269115B2 (https=) |
| CA (1) | CA3025162A1 (https=) |
| WO (1) | WO2017205014A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12016502073B1 (en) | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| CN104011207B (zh) | 2011-10-31 | 2018-09-18 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| MA44780A (fr) | 2016-04-28 | 2019-03-06 | Chugai Pharmaceutical Co Ltd | Préparation contenant un anticorps |
| KR102591955B1 (ko) | 2016-07-29 | 2023-10-19 | 추가이 세이야쿠 가부시키가이샤 | 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체 |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| JP7556687B2 (ja) * | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| EP3616720B1 (en) | 2017-03-29 | 2021-02-17 | Shionogi&Co., Ltd. | Pharmaceutical composition for cancer treatment |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| AR113142A1 (es) | 2017-09-29 | 2020-01-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo |
| AU2018361430B2 (en) | 2017-11-01 | 2025-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| JP2019151621A (ja) * | 2018-02-28 | 2019-09-12 | 学校法人藤田学園 | Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物 |
| CN110357960A (zh) * | 2018-04-10 | 2019-10-22 | 广州爱思迈生物医药科技有限公司 | 抗体及抗体改造方法 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| US20220235144A1 (en) | 2019-03-04 | 2022-07-28 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| EP4021579A1 (en) * | 2019-08-30 | 2022-07-06 | Qilu Puget Sound Biotherapeutics Corporation | Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof |
| MX2022003744A (es) * | 2019-09-30 | 2022-07-21 | Adimab Llc | Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas. |
| CA3160436A1 (en) * | 2019-12-17 | 2021-06-24 | Jack Chongyang LI | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof |
| CN115943210A (zh) * | 2020-01-20 | 2023-04-07 | 中外制药株式会社 | 配体结合融合蛋白 |
| WO2022023559A1 (en) * | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| MX2023002125A (es) * | 2020-08-20 | 2023-04-26 | Amgen Inc | Proteínas de unión a antígenos con disulfuro no canónico en la región fab. |
| JP7610302B2 (ja) * | 2020-08-28 | 2025-01-08 | ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド | Ｃｃｒ８抗体及びその用途 |
| CN114437226A (zh) * | 2020-11-05 | 2022-05-06 | 杭州菁因康生物科技有限公司 | 制备双特异性抗体的方法 |
| EP4294531A4 (en) * | 2021-02-18 | 2025-07-16 | Qilu Puget Sound Biotherapeutics Corp | COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES |
| CN112961245B (zh) * | 2021-02-24 | 2023-07-25 | 重庆精准生物技术有限公司 | 一种靶向cd96的双特异性抗体及其制备方法和用途 |
| JP2024515301A (ja) * | 2021-04-20 | 2024-04-08 | アムジエン・インコーポレーテツド | 多重特異性及び一価のｉｇｇ分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布 |
| JP2024517671A (ja) * | 2021-04-23 | 2024-04-23 | チマゲン・バイオサイエンシズ，リミテッド | ヘテロ二量体抗体およびその抗原結合断片 |
| JP2024530402A (ja) * | 2021-07-12 | 2024-08-21 | ジェネンテック， インコーポレイテッド | 抗体－リパーゼ結合を減少させるための構造 |
| CA3224853A1 (en) | 2021-07-14 | 2023-01-19 | Gautham GAMPA | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
| JP2024527582A (ja) * | 2021-07-19 | 2024-07-25 | 中外製薬株式会社 | 融合ポリペプチドを用いるプロテアーゼ媒介性の標的特異的サイトカイン送達 |
| EP4405398A4 (en) * | 2021-09-21 | 2025-10-29 | Qilu Puget Sound Biotherapeutics Corp | FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES |
| WO2023160517A1 (zh) * | 2022-02-22 | 2023-08-31 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| US20260022169A1 (en) * | 2022-03-11 | 2026-01-22 | Elpiscience Biopharma, Ltd. | Modified antibodies and uses thereof |
| CN118946366A (zh) * | 2022-04-13 | 2024-11-12 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2024002074A1 (zh) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2024002226A1 (zh) * | 2022-06-30 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN119604525A (zh) | 2022-07-22 | 2025-03-11 | 信达生物制药(苏州)有限公司 | 促进多特异性抗体的重链和轻链同源配对的突变体 |
| WO2024143442A1 (ja) | 2022-12-27 | 2024-07-04 | 中外製薬株式会社 | 会合が制御されたポリペプチド |
| WO2024158961A1 (en) * | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2025059037A1 (en) * | 2023-09-11 | 2025-03-20 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof |
| WO2025117485A1 (en) * | 2023-11-29 | 2025-06-05 | Qilu Puget Sound Biotherapeutics Corporation | Anti-il33 and anti-tslp antibodies, and mixtures |
| WO2025228542A1 (en) | 2024-05-03 | 2025-11-06 | Genmab B.V. | Method for co-expression of a plurality of antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| ES2273202T3 (es) * | 2003-01-07 | 2007-05-01 | Symphogen A/S | Procedimiento para producir proteinas policlonales recombinantes. |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101675075B (zh) * | 2007-03-01 | 2014-06-18 | 西福根有限公司 | 重组抗表皮生长因子受体抗体组合物 |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| JP5746040B2 (ja) | 2008-12-03 | 2015-07-08 | ゲンマブ エー／エス | 定常領域の中に改変を有する抗体変種 |
| US20120020952A1 (en) | 2009-01-26 | 2012-01-26 | Genmab A/S | Methods for producing mixtures of antibodies |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| CA2808154A1 (en) | 2010-08-13 | 2012-02-16 | Medimmmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| US20140038285A1 (en) | 2011-03-11 | 2014-02-06 | Amgen Inc. | Method of correlated mutational analysis to improve therapeutic antibodies |
| EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| IN2013MN01438A (https=) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| LT2794905T (lt) * | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| SI2838917T1 (sl) * | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| WO2013166594A1 (en) | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| AU2013339038B2 (en) * | 2012-11-05 | 2017-12-21 | Zenyaku Kogyo Kabushikikaisha | Antibody and antibody composition production method |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP3878964A1 (en) | 2012-11-27 | 2021-09-15 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| EP2925785A4 (en) | 2012-11-28 | 2016-11-16 | Zymeworks Inc | MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF |
| US10118971B2 (en) | 2013-03-13 | 2018-11-06 | Ibentrus, Inc. | Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor |
| US10047167B2 (en) | 2013-03-15 | 2018-08-14 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
| SG11201600734YA (en) | 2013-07-31 | 2016-02-26 | Amgen Inc | Stabilization of fc-containing polypeptides |
| EP3080158A4 (en) | 2013-12-09 | 2018-03-21 | Adimab, LLC | Polyclonal mixtures of antibodies, and methods of making and using them |
| ES2936810T3 (es) * | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
| CA3042249A1 (en) * | 2016-11-08 | 2018-05-17 | Qilu Puget Sound Biotherapeutics Corporation | Anti-pd1 and anti-ctla4 antibodies |
-
2017
- 2017-05-02 AU AU2017269115A patent/AU2017269115B2/en not_active Expired - Fee Related
- 2017-05-02 EP EP17723832.6A patent/EP3463451A1/en active Pending
- 2017-05-02 CN CN201780043870.9A patent/CN109475627B/zh active Active
- 2017-05-02 JP JP2018562201A patent/JP7301540B2/ja active Active
- 2017-05-02 CA CA3025162A patent/CA3025162A1/en active Pending
- 2017-05-02 WO PCT/US2017/030676 patent/WO2017205014A1/en not_active Ceased
- 2017-05-05 US US16/303,611 patent/US11130808B2/en active Active
-
2021
- 2021-09-23 US US17/483,630 patent/US20220073615A1/en active Pending
- 2021-11-11 JP JP2021184049A patent/JP2022010244A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520063A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| JP2019532619A5 (https=) | ||
| JP2015214563A5 (https=) | ||
| JP2015227386A5 (https=) | ||
| JP2018516546A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2018533371A5 (https=) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2018510617A5 (https=) | ||
| JP2016512551A5 (https=) | ||
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2018506277A5 (https=) | ||
| JP2020514277A5 (https=) | ||
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| JP2017520575A5 (https=) | ||
| TW201333039A (zh) | 雙可變域免疫球蛋白及其用途 | |
| HRP20221538T1 (hr) | Anti-transtiretinska antitijela | |
| JP2015528003A5 (https=) | ||
| HRP20130883T4 (hr) | Međuvrsno specifična cd3-epsilon-vežuća domena | |
| JP2015518479A5 (https=) | ||
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2022534674A (ja) | タンパク質を多量体化する変異体ドメイン及びその分離 | |
| JP2021507677A5 (https=) |